true
The Precision Blog
100% sourced from leading minds on the front lines of research
All articles
-
Read: Case Study: Running an Adaptive Early-Phase RAS Oncology Trial
-
Read: Precision for Medicine Re-approved as a CIR-Eligible R&D Partner Under the French Research Tax Credit Programme 
Precision for Medicine Re-approved as a CIR-Eligible R&D Partner Under the French Research Tax Credit Programme
-
Read: The Cells Don't Have to Be Alive: Immunophenotyping post CAR-T Therapy 
The Cells Don't Have to Be Alive: Immunophenotyping post CAR-T Therapy
-
Read: Why In-Country Project Management Is a Non-Negotiable in APAC Trials 
Why In-Country Project Management Is a Non-Negotiable in APAC Trials
-
Read: The Operational Reality of Clinical Trial Technology 
The Operational Reality of Clinical Trial Technology
-
-
Read: Case Study: FIH Radiopharmaceutical Trial Across South Korea and US 
Case Study: FIH Radiopharmaceutical Trial Across South Korea and US
-
Read: Case Study: Global Phase 2 Drug Delivery in Advanced Colorectal Cancer 
Case Study: Global Phase 2 Drug Delivery in Advanced Colorectal Cancer
-
Read: Case Study: Managing Complexity in an Autologous Cell Therapy Trial 
Case Study: Managing Complexity in an Autologous Cell Therapy Trial
-
-
Read: How Investigator Engagement Builds Enrollment Momentum 
How Investigator Engagement Builds Enrollment Momentum
-
Read: Case Study: Nectin 4 Biomarker Testing for Oncology Clinical Programs 
Case Study: Nectin 4 Biomarker Testing for Oncology Clinical Programs
-
Read: Has the rest of the world finally caught up with Latin America? 
Has the rest of the world finally caught up with Latin America?
-
Read: Case Study: Rapid Execution of Assay Validation Rescued Global Study 
Case Study: Rapid Execution of Assay Validation Rescued Global Study
-
-
Read: Clinical AI at Scale: Why Trust Matters More Than Speed 
Clinical AI at Scale: Why Trust Matters More Than Speed
-
-
Read: Hidden Strategic Edge in Clinical Trials: Financial Project Management 
Hidden Strategic Edge in Clinical Trials: Financial Project Management
-
Read: Why Most Early Autoimmune Trials Fail to Yield Decision-ready Evidence 
Why Most Early Autoimmune Trials Fail to Yield Decision-ready Evidence
-
Read: Why Global Oncology Evidence May Not Support U.S. Regulatory Approval 
Why Global Oncology Evidence May Not Support U.S. Regulatory Approval
-
Read: Early-Phase Oncology Trials in Ireland: Why START Dublin Is a High-Performing Site for Sponsors 
Early-Phase Oncology Trials in Ireland: Why START Dublin Is a High-Performing Site for Sponsors
-
Read: Receptor Occupancy in the Era of Multispecific Therapeutics 
Receptor Occupancy in the Era of Multispecific Therapeutics
-
-
Read: Case Study: Prescreening Intel Restores Phase 3 Colorectal Enrollment 
Case Study: Prescreening Intel Restores Phase 3 Colorectal Enrollment
-
Read: Case Study: Theranostic Radiopharm Trial and Evolving FDA Expectations 
Case Study: Theranostic Radiopharm Trial and Evolving FDA Expectations
-
-
Read: Why APAC Is Becoming a Design Decision 
Why APAC Is Becoming a Design Decision
-
-
Read: Case Study: Delivering an Early-Phase Autoimmune Trial Across Regions 
Case Study: Delivering an Early-Phase Autoimmune Trial Across Regions
-
-
Read: Early‑Phase Autoimmune Drug Development: Trial Design, Biomarkers and Statistical Strategies 
Early‑Phase Autoimmune Drug Development: Trial Design, Biomarkers and Statistical Strategies
-
Read: Case Study: Advancing IHC Assays from RUO to Clinical Trials and CDx 
Case Study: Advancing IHC Assays from RUO to Clinical Trials and CDx
-
-
Read: China’s New Drug Regulatory Framework Positions the Country as a Global Hub for Innovative Medicine Launches 
China’s New Drug Regulatory Framework Positions the Country as a Global Hub for Innovative Medicine Launches
-
Read: Bringing Early Phase Oncology Closer to Patients in Los Angeles 
Bringing Early Phase Oncology Closer to Patients in Los Angeles
-
Read: Radiopharmaceutical Clinical Trials: What Sponsors Need to Know About Selecting a CRO 
Radiopharmaceutical Clinical Trials: What Sponsors Need to Know About Selecting a CRO
-
-
Read: Cancer Is the Enemy: How Phase I Oncology Teams Accelerate Drug Development 
Cancer Is the Enemy: How Phase I Oncology Teams Accelerate Drug Development
-
Read: Expanding Clinical Trial Execution in Greater China: Beijing, Shanghai, Hong Kong & Taiwan 
Expanding Clinical Trial Execution in Greater China: Beijing, Shanghai, Hong Kong & Taiwan
-
-
Read: Strategic Management of Radiopharmaceutical Trial Complexity 
Strategic Management of Radiopharmaceutical Trial Complexity
-
Read: Case Study: How Monitoring Caught a Silent PK Crisis in a CAR T Rescue 
Case Study: How Monitoring Caught a Silent PK Crisis in a CAR T Rescue
-
Read: What the EMA–FDA AI Principles Really Mean for Clinical Development & Regulatory Affairs 
What the EMA–FDA AI Principles Really Mean for Clinical Development & Regulatory Affairs
-
-
Read: Case Study: Scaling a First Line NSCLC Trial in a Hesitant Market 
Case Study: Scaling a First Line NSCLC Trial in a Hesitant Market
-
-
Read: Developing a Comprehensive Strategy for Implementing AI & Multi-Omics for Translational Research 
Developing a Comprehensive Strategy for Implementing AI & Multi-Omics for Translational Research
-
Read: The Collaborative CRO Partnership Model: Amplifying Your Team 
The Collaborative CRO Partnership Model: Amplifying Your Team
-
Read: EMA PRIME Scheme Explained: Eligibility, Benefits, Risks, and When to Apply 
EMA PRIME Scheme Explained: Eligibility, Benefits, Risks, and When to Apply
-
You've reach the end
